ArticleDiscover oncology2025
5,7,2',6'- Tetrahydroxyflavone affects the progression of ovarian cancer via hsa-miR-495-3p-ACTB/HSP90AA1 pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundScutellariae Radix (SR), a traditional Chinese medicine, has been shown to have potential anti-cancer properties. PURPOSE: To explore the mechanism of inhibiting ovarian cancer (OC) progression by SR.
methodsThe key active ingredient (5,7,2',6'-Tetrahydroxyflavone, TF) and key targets (ACTB and HSP90AA1) of SR were screened by the network pharmacology method. CCK-8 reagent, Transwell assay, and Annexin-V-FITC kit were used to evaluate the effects of TF on OC cell viability, migration, and apoptosis. The upstream microRNAs (miRNAs) of ACTB and HSP90AA1 were predicted by the starBase database. Important miRNAs related to OC were mined using gene expression datasets in the GEO database. RT-qPCR and Western blotting experiments were used to detect miRNA or gene expression.
resultsTF inhibited OC cell viability/migration and induced apoptosis in a concentration-dependent manner. Hsa-miR-495-3p was identified to be a key miRNA in OC, whose expression was lacking in OC cells. ACTB and HSP90AA1 expressed highly in OC cells. Hsa-miR-495-3p mimics reduced ACTB and HSP90AA1 expression. Hsa-miR-495-3p inhibitor and overexpression of ACTB or HSP90AA1 reversed the inhibitory effect of TF on OC cells.
conclusionTF, an active ingredient of SR, hindered OC progression through the hsa-miR-495-3p-ACTB/HSP90AA1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.